Sanofi India Limited — PPTs, 29-10-2025: Investor Presentation

Sanofi India is undergoing a pivotal business model transformation for sustainable, profitable growth, primarily focusing on its Insulin franchise and a successful partnership model for legacy brands.

**Business Performance:** For the nine-month period ending September 2025, Net Sales grew +3% YoY to ₹1162.4 Cr, with Domestic sales up +2%. The Insulin and Partnership segments each saw +5% YoY growth, while the Diabetes segment declined -45%. Q3 2025 marked strong performance with total Net Sales surging +53% YoY to ₹273.8 Cr, and Domestic Sales up +13%. Profit Before Tax (PBT) for Q3 rose +15% to ₹129.7 Cr, with PBT margin improving to 29% from 23% last year. Year-to-date PBT was up +10% to ₹389 Cr, with margin at 29%. Operating expenses in Q3 reduced by 30% YoY, now representing 22% of net sales, down from 31%.

**Growth Drivers/Strategy:** The company is modernizing its business, with a new organization focused on the Insulin franchise. Key strategies include winning with its Basal and Premix portfolio, market expansion via digital outreach and public sector engagement, and innovative customer journeys utilizing AI-enabled capabilities. The successful launch of Soliqua is also highlighted.

**Management Commentary / Outlook:** Management indicates the strategic transformation is complete, positioning the company to capture India's high-growth diabetes opportunity through strong execution and operational excellence.